17 years old | 0
black | 0
African | 0
female | 0
admitted to the hospital | 0
gradual-onset bi-frontal headache | -336
insomnia | -336
subjective fevers | -336
restlessness | -240
third-person auditory hallucinations | -240
acute schizoaffective disorder | -240
psychological stressors | -240
death anniversary of her mother | -240
imminent final high-school national examinations | -240
documented fevers | -168
orofacial dyskinesias | -168
tongue-biting | -168
agitation | -168
neuroleptic malignant syndrome | -168
coma | -144
transferred to tertiary referral hospital | -144
temperature of 39Â°C | 0
tachycardia | 0
Glasgow Coma Scale 7/15 | 0
grimacing | 0
tongue biting | 0
bruxism | 0
hyper-salivation | 0
abnormal arm movements | 0
intubated | 0
mechanically ventilated | 0
admitted to intensive care unit | 0
elevated CSF pressures | 0
CSF white cell count 115/mm3 | 0
CSF lymphocytes 98% | 0
negative PCR for bacterial meningo-encephalitis pathogens | 0
negative PCR for tuberculosis meningo-encephalitis pathogens | 0
negative PCR for herpes meningo-encephalitis pathogens | 0
contrast-enhanced MRI brain scan leptomeningeal enhancement | 0
MRI sulcal hyperintensities | 0
EEG diffuse slowing | 0
EEG no epileptiform discharges | 0
treated for viral encephalitis | 0
stopped viral encephalitis treatment after negative PCRs | 0
probable NMDARE diagnosis | 0
intravenous methylprednisolone | 0
intravenous immunoglobulins | 0
oral levetiracetam | 0
tetrabenazine | 0
midazolam infusion | 0
propofol infusion | 0
maxillo-mandibular fixation | 0
serum positive for NMDA receptor antibodies | 7
CSF positive for NMDA receptor antibodies | 7
MRI pelvis no teratoma | 7
repeat MRI brain resolution of meningeal enhancement | 15*24
repeat MRI brain resolution of sulcal hyperintensities | 15*24
Glasgow Coma Scale 8/15 | 15*24
persistent dyskinesias | 15*24
repeated IVMP course | 15*24
plasma exchange | 15*24
weekly rituximab | 15*24
right brachial deep vein thrombosis | 15*24
treated with low-molecular weight heparin | 15*24
tongue maceration | 15*24
surgical debridement | 15*24
tracheostomy | 15*24
percutaneous endoscopic gastrostomy | 15*24
high-grade fevers | 21*24
multi-drug resistant Pseudomonas aeruginosa | 21*24
Klebsiella pneumoniae | 21*24
appropriate intravenous antibiotics | 21*24
carbapenems | 21*24
continued debridement | 21*24
septic shock | 30*24
multi-organ dysfunction | 30*24
death | 30*24
